{"disease":{"id":"epidermolysis-bullosa-dystrophica-recessive","name":"epidermolysis bullosa dystrophica recessive"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02810951","title":"A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Castle Creek Biosciences, LLC.","has_results":true},{"nct_id":"NCT04186650","title":"Ex Vivo Gene Therapy Clinical Trial for RDEB Using Genetically Corrected Autologous Skin Equivalent Grafts","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT03605069","title":"A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Phoenicis Therapeutics","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}